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Mycobacterium tuberculosis is reputed to have the
highest annual global mortality among all of the
pathogens1. The rise in tuberculosis (TB) incidence
over the last two decades is partly due to TB deaths
in HIV-infected patients and partly due to the
emergence of multidrug resistant strains of the
bacteria. This rapid increase in the disease has led to
potential funding arrangements aimed at a large effort
towards stopping this disease before it becomes a
global epidemic. Due to its slow growth and high
virulence it is extremely difficult to work with the
TB bacterium. However, rapidly evolving
mycobacterial genomics with complete genome
sequences known along with powerful bioinformatics
approaches, one can realize better therapeutics and
prophylactics in the near future2. A comparative
genomic analysis of these species has a potential to
reveal the genetic basis of disease phenotypes, which
will be invaluable for the development of much
needed drugs and newer vaccines.
Problem of multi drug resistant tuberculosis
(MDR-TB)
One of the classical threats of the tuberculosis
epidemic has been the MDR-TB. Use, and often abuse
or misuse, of antimicrobial agents has encouraged
the evolution of bacteria toward resistance, resulting
often in therapeutic failure. There are evidences that
bacteria have the ability to adapt to this deficit and
recover fitness on serial passage1. Resistance to
antituberculosis drugs has been a problem since the
era of chemotherapy began. After dramatic outbreaks
of MDR-TB in the early 1990s, resistance became
recognized as a global problem. MDR-TB now
threatens the inhabitants of countries in Europe, Asia,
Africa, and the Americas2. An understanding of the
molecular basis of drug resistance may contribute to
the development of new drugs3. Management of
MDR-TB relies on prompt recognition and treatment
with at least 3 drugs to which an isolate is susceptible.
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Tuberculosis (TB) has been declared as a global health emergency by the World Health Organization
(WHO). This has been mainly due to the emergence of multiple drug resistant strains and the synergy
between tubercle bacilli and the human immunodeficiency virus (HIV). Genomic analysis of strains
for outbreak investigations is in vogue for about a decade now. However, information available from
whole genome sequencing efforts and comparative genomics of laboratory and field strains is likely
to revolutionize efforts towards understanding molecular pathogenesis and dissemination dynamics
of this dreaded disease. Genomic information is also going to fuel discovery projects where new
targets will be identified and explored towards a new drug for TB. Besides this, efforts of information
technologists, chemists, population biologists, freelance workers, media persons, non-governmental
organizations and administrators to needed to handle the problem of tuberculosis to prevent it from
becoming a pandemic.
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The roles of drug containing environments, and the
immunological status of the host and bacterial
molecular mechanisms of development of drug
resistance to M. tuberculosis have been examined and
results are helpful in implementation of modified
drug regimens in tuberculosis control programmes.
Multidrug resistant strains of M. tuberculosis
seriously threaten tuberculosis control and prevention
efforts. Molecular studies of the mechanism of action
of antitubercular drugs have elucidated the genetic
basis of drug resistance. Drug resistance in M.
tuberculosis has been primarily attributed to the
mutations in the drug target genes, however, the
presence of efflux pumps in clinical MDR isolates
cannot be ruled out4. These mutations lead either to
an altered target or to a change in titration of the drug.
A diverse array of strategies is already available to
assist in rapid detection of drug resistance-associated
gene mutations. In spite of remarkable advances in
this area, much remains to be learned about the
molecular genetic basis of drug resistance in  M.
tuberculosis. During the last decade, there has been
a marked increase in the number and gravity of
tuberculosis cases both in developing countries and
in industrialized nations. One of the more insidious
consequences of this resurgence has been the recent
emergence of nosocomial transmission of multi drug
resistant strains of  M. tuberculosis, thus creating
untreatable forms of the disease and these strains may
become widespread. That the various clinical isolates
of M. tuberculosis are geographically partitioned at
the global level. Ahmed et al5,6 has provided evidence
to the concept of geographic genomics7.
The TB- HIV symphony: Supporting the idea of
low virulent clones
The emergence of the HIV/acquired
immunodeficiency syndrome (AIDS) pandemic has
led to major shift in our approaches towards
epidemiological studies of TB both in resource poor
and developed countries, with HIV infection
becoming a risk factor for the development of active
TB infection. This might be a consequence of
increased re-activation of previously acquired,
dormant bacilli and an increase in susceptibility to
both re-infection and primary infection. Studies
involving DNA fingerprinting of M.  tuberculosis
isolates obtained from AIDS patients by the technique
of restriction fragment length polymorphism (RFLP)
analysis showed that re-infection and new infection
both occur in AIDS patients5. It has been speculated
that the HIV/AIDS patients constituting an ecological
niche for M. tuberculosis, where less virulent strains
multiply freely without the selection pressure
provided by an immunocompetent patient.
Consequently, it should be possible to differentially
identify pathogenic bacterial clones and differentiate
them on the basis of epidemiological parameters
related to co-infection, relapse versus recent infection
and multiple drug resistance. Recently, one
study6 has been conducted under the auspices of the
M. tuberculosis evolutionary genomics interest group,
where significantly different genotypes were observed
for HIV-associated tubercle bacilli as compared to
bacilli recovered from non-HIV patients. This has
been the only study of its kind in the post genomic
scenario where high resolution genomic pattern
analysis was systematically applied to a well
characterized strain collection from a clinically tested
patient population. While statistically significant
association of a clone to the disease outbreak in a
community may reflect increased fitness of the
genome, it can be suggested that this phenomenon
should be observed in multiple settings before they
can be linked with certainty to a particular host
population. Frequent travel and social links among
the people of economically productive and sexually
active age groups as seen in some African and South
American countries, often provide for fast
multiplication of low virulent strains and therefore
high clustering is seen in such settings.
The post genomic approaches
New developments in molecular biology and
functional genomics have fostered major advances
in our understanding of genetic variability among M.
tuberculosis.  Complete genome sequence
information8 has been released for this organism
opening new vistas in diagnosis, epidemiology and
vaccine development. Automated DNA sequencing
allows for the direct comparison of specific genes
among large populations of isolates, and
determination of complete genomic sequence of two
strains together with new technologies like DNA
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microarrays and computational biology, has provided
a whole genome perspective on genomic content,
gene regulation, and metabolism.
The face of infection epidemiology has changed
in the post genomic scenario. Bacterial genome
signatures permit whole genome comparisons
between different bacterial strains or isolates by using
differential amplification techniques and automated
genotyping for the determination of genetic signatures
or barcodes. These signatures could be a group of
markers or DNA fragments of unique sizes. In this
way, gene deletions may be readily identified that
correlate with alteration in virulence or other
phenotypes.
The use of differential expression to monitor
whole genome expression is now a powerful
approach, which will result in definition of
differentially expressed genes important in
pathogenesis, and will provide useful targets for
rational design of new drugs and vaccine candidates
for M. tuberculosis. These studies are likely to
confirm the reality of “transcriptomics” as a technical
deliverable for hypothesis driven research into
mycobacterial pathogenesis, vaccine and drug
research.
The emergence of protein-based analysis or
proteomics is likely to facilitate determination of
changes in the expression profile that leads to
pathogenicity, drug resistance and immune responses.
This approach has a very high potentiality and
accuracy to identify proteins involved in
pathogenicity and drug resistance leading to
development of medical intervention. Similar
approaches can be adopted to understand M.
tuberculosis pathogenicity and multidrug resistance
among different strains.
The recent accumulation of copious data about the
extent and nature of genetic and phenotypic variation
in tubercle bacilli provides an unprecedented
opportunity to determine the phenotypic
consequences of genetic polymorphism in this
organism. However, a coherent synthesis of this
knowledge is lacking, reflecting the formidable
challenges of this endeavour. Because environmental
and host factors clearly contribute to the clinical and
epidemiologic behaviour of strains, these factors must
be carefully integrated into the investigative process.
Post genomic databases for epidemiologists
A large number of molecular markers have been
made available for epidemiological and evolutionary
studies as a result of comparative genomics studies
(Fig.). These markers include Mycobacterial
interspersed repeat units-variable number tandem
repeats (MIRU-VNTRs)9, fluorescent amplified
fragment length polymorphism (FAFLPs)6 and large
genomic deletions10. The present day challenge is to
compile standardized fingerprint patterns originating
from highly networked, multi-centric, genotypic
analyses in the databases for interlaboratory use and
future references7.  This requires an accurate
measurement of fragment lengths. Analysis via
molecular weight markers in adjacent lanes is
straightforward and can be done automatically on
digitated images. A correction for the variation in
migration rates and gel distortion is achieved by co-
electrophoresis in each lane of both sample and
marker fragment. One option is the use of invariant
fragments with known lengths as internal markers.
Digitated images in a standard graphical file may be
obtained as scanned autoradiographs. These data can
be imported in gel analysis software, which carries
out the normalization and fragment sizing for analysis
by the dedicated software. Many databases have been
developed recently for rapid genotypic searches and
comparisons on the world-wide web: SpolDB:
Spoligotyping resource database at Institut Pasteur
of Guadilope (http://www.cdc.gov/ncidod/EID/
vol7no3/sola_data.htm) Tbase: RFLP resource
database at RIVM, The Netherlands (https://
h y p o c r a t e s . r i v m . n l / b n w w w / I S 6 1 1 0 - R F L P -
bands.htm) AmpliBASE: AFLP resource database at
CDFD Hyderabad (http:www.cdfd.org.in/amplibase)
MiruDB:VNTR resource database at IBL Lille,
France (http://www.ibl.fr/mirus/mirus.html)
Post genomic discovery efforts: TB structural
genomics
It is quite unfortunate to realize that while the
world is faced with the horrors of TB epidemic, no
novel compound has been introduced for widespread
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treatment of this disease after rifampicin was
developed in 1963. At this point, however, it is
believed that new chemotherapies for treatment of
TB should have the following major objectives: (i)
development of faster acting drugs to shorten the
duration of treatment; (ii) development of novel
antimicrobials to counter the emergence of bacteria
resistant to current therapies; and (iii) development
of chemotherapeutics that specifically target dormant
bacilli and hence provide more effective treatment
of latent TB infections.
In the post genomic scenario, a strong emphasis
has been paid on structural genomics based discovery
of new powerful drugs. Structural genomics is the
large scale determination and analysis of protein
structures. It is a new field that has been boosted by
major technological advances in structure
determination and by the availability of as many as
95 to 200 completed genome sequences related to
many microbial and protozoan species. Several
computational methods can predict the biological
roles of proteins by analyzing functional relationships
among proteins rather than sequence similarities.
Three of these methods are phylogenetic profiling,
domain fusion and gene clustering. These methods
can help in identifying potential drug targets such as
proteins functionally linked to known targets of anti-
TB drugs and to proteins known to be essential for
bacterial survival. Inhibiting these functionally
related proteins should have a similar effect on the
organism as inhibiting the present drug targets, since
the same processes or pathways would be disrupted.
An international effort in the form of the TB
Structural Genomics Consortium11 has been a most
successful partnership of investigators working on
different targets throughout the world. Objectives of
this partnership include determining the structures
of many of the mycobacterial proteins facilitating
drug discovery efforts using high throughput
screening, genetic identifications of key TB genes,
and structure-based approaches. Other proteins that
might be good targets for anti-TB therapy include
extracellular proteins that are involved in virulence,
and persistence determinants, since the M.
tuberculosis cell envelope is impermeable to many
Fig. Screen dump of AmpliBASE MT®, a M. tuberculosis diversity knowledgebase, that is based on MIRU(A) and FAFLP(B)
markers.
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antibacterial agents. Potential therapeutic targets also
include secreted antigens and proteins involved in
iron acquisition, which is a critical process for M.
tuberculosis survival. These proteins include iron
regulatory proteins and enzymes involved in the
production of secreted iron siderophores such as
exocholins and mycobactins. Proteins specific to
tubercle bacilli might constitute possible targets,
since these may provide adaptations exclusive to the
virulence and pathogenicity of mycobacteria. In
particular, 10 per cent of the M. tuberculosis genome
consists of genes that encode M. tuberculosis-specific
PE, PPE and PE-PGRS proteins. The PE family is
named after the presence of the motif proline-gluamic
acid (PE) at positions 8 and 9 in a highly conserved
N-terminal domain of approximately 110 amino
acids, the C-terminal region is however, variable
within the family. The PPE family resembles the PE
family with a highly conserved N-terminal region
(about 180 amino acids), containing the motif
proline-prolineglutamic acid at positions 7-9. Lastly,
the (PE-PGRS) (polymorphic GC-rich sequence)
family represents an extension of the PE protein
family with multiple repeats of glycine-glycine-
alanine (asparagine) motifs. The function or functions
of these proteins are unknown though they have been
implicated in virulence and immune surveillance12,13.
Conclusion and expert opinion
In the post genomic scenario, future of TB
elimination holds a lot of promise but it is yet to be
realized. With the unravelling of the M. tuberculosis
genome, newer paradigms in the areas of
epidemiology, evolution and diagnostics are almost
certain. On the discovery front, scientists can now
selectively target enzymes of M. tuberculosis which
display strong antigenic attributes14.  Genetic
products of mycobacteria can be modified to cause
their own death. The international initiative under
the auspices of the Structural Genomics Consortium
is all set to harvest the fruits of such a new biology.
In the future, the distinction between drugs,
immunomodulators and vaccines may disappear
leading to amalgamation of all these as a super
antimycobacterial to rid the world from the deadly
shadow of TB. With the unprecedented growth of
bioinformatics and comparative genomics, state of
the art technologies are essential to utilize the vast
gene pools sitting in the databases. Genomic
discovery alone will not be sufficient to tackle the
problem. Apart from basic scientists, the role of health
care workers, clinicians and epidemiologists, public-
private partnerships and the non- government
organizations will be highly needed on all the frontiers.
Acknowledgment
Authors thank all the collaborators of M. tuberculosis
evolutionary genomics interest group and Centre for DNA
Fingerprinting and Diagnostics, Hyderabad for supporting this
initiative. The generous support from Department of
Biotechnology (DBT) and Council for Scientific & Industrial
Research (CSIR), New Delhi is gratefully acknowledged.
References
1. Sharma SK, Mohan V. Multidrug-resistant tuberculosis.
Indian J Med Res 2004; 120 : 354-76.
2. Chakhaiyar P, Hasnain SE. Defining the mandate of
tuberculosis research in a post genomic era. Med Princ Prac
2004; 13 : 177-84.
3. Siddiqi N, Shamim M, Hussain S, Choudhary RK, Ahmed
N, Prachee, et al. Molecular characterization of multidrug-
resistant isolates of Mycobacterium tuberculosis from
patients in north India. Antimicrob Agents Chemother 2002;
46 : 443-50.
4. Siddiqi N, Das R, Pathak N, Banerjee S, Ahmed N,
Katoch VM, et al. Mycobacterium tuberculosis isolate with
a distinct genomic identity overexpresses a TAP like efflux
pump. Infection 2004; 32 : 109-11.
5. Ahmed N, Alam, M, Rao KR, Kauser F, Kumar NA, Qazi,
NN, et al. Molecular genotyping of a large, multi-centric
collection of tubercle bacilli indicates geographical
partitioning of strain variation: Implications in global
epidemiology of M. tuberculosis. J Clin Microbiol 2004;
42: 3240-7.
6. Ahmed N, Caviedes L, Alam M, Rao KR, Sangal V, Sheen
P, et al. Distinctiveness of Mycobacterium tuberculosis
genotypes from human immunodeficiency virus type 1-
seropositive and -seronegative patients in Lima, Peru. J Clin
Microbiol 2003; 41: 1712-6.
7. Majid AA, Ahmed N, Rao KR, Ghousunnissa S, Kausar F,
Bose B, et al .  AmpliBASE MT: A Mycobacterium
tuberculosis diversity knowledgebase. Bioinformatics 2002;
20: 989-92.
GENOMICS OF M. TUBERCULOSIS: OLD THREATS & NEW TRENDS
212 INDIAN J MED RES, OCTOBER 2004
8. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C,
Harris D, et al. Deciphering the biology of Mycobacterium
tuberculosis from the complete genome sequence. Nature 1998;
393 : 537-44.
9. Supply P, Lesjean S, Savine E, Kremer K, van Soolingen D,
Locht C. Automated high-throughout genotyping for study of
global epidemiology of Mycobacterium tuberculosis based on
mycobacterial inter-spersed repetitive units. J Clin Microbiol
2001; 39 : 3563-71.
10. Brosch R,  Gordon SV, Marmiesse M, Brodin P,  Buchrieser C,
Eiglmeier K, et al. A new evolutionary scenario for the
Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA
2002; 99 : 3684-9.
11. Goulding CW, Apostol M, Anderson DH, Gill HS, Smith CV,
Kuo MR, et al. The TB Structural Genomics Consortium:
providing a structural foundation for drug discovery. Curr Drug
Targets Infect Disord 2002; 2 : 121- 41.
12. Choudhary RK, Mukhopadhyay S, Chakhaiyar P, Sharma N,
Murthy KJ, Katoch VM, et al. PPE antigen Rv2430c of
Mycobacterium tuberculosis induces a strong B-cell response.
Infect Immun 2003; 71 : 6338-43.
13. Chakhaiyar P, Nagalakshmi Y, Aruna B, Murthy KJ, Katoch
VM, Hasnain SE. Regions of high antigenicity within the
hypothetical PPE_MPTR open reading frame, Rv2608 show a
differential humoral response and a low T cell response in various
categories of patients with tuberculosis. J Infect Dis 2004; 190 :
1237-44.
14. Banerjee S, Nandyala A, Podili R, Katoch VM,
Murthy KJ, Hasnain SE. Mycobacterium tuberculosis isocitrate
dehydrogenases show strong B-cell response and distinguish
vaccinated controls from TB patients. Proc Natl Acad Sci USA
2004; 101: 12652-7.
Reprint requests : Dr S.E. Hasnain, Director, Centre for DNA Fingerprinting & Diagnostics, ECIL Road, Nacharam,
Hyderabad 500076, India
e-mail: hasnain@cdfd.org.in
